BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting

  March 6, 2025

   · 

  6 min read
• Press Releases

  Frazier Life Sciences Appoints Gerald Nepom as Senior Advisor

  March 6, 2025

   · 

  2 min read
• Press Releases

  bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

  March 6, 2025

   · 

  6 min read
• Press Releases

  Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

  March 6, 2025

   · 

  5 min read
• Press Releases

  Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

  March 6, 2025

   · 

  3 min read
• Press Releases

  NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology

  March 6, 2025

   · 

  6 min read
• Press Releases

  Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

  March 6, 2025

   · 

  4 min read
• Press Releases

  Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)

  March 6, 2025

   · 

  6 min read
• Press Releases

  Evidation Appoints Leslie Oley Wilberforce as CEO

  March 6, 2025

   · 

  3 min read
• Press Releases

  ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors

  March 6, 2025

   · 

  4 min read